Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_2
2
40%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Completed2
unknown1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
N/A1 (25.0%)

Trials by Status

completed240%
unknown120%
terminated120%
withdrawn120%

Recent Activity

0 active trials
Showing 5 of 5
unknown

Gene Signatures Searching of Sensitivity/Resistance to Neoadjuvant Radiotherapy in Patients With Resectable STS

NCT05739084
completednot_applicable

Immune Boost In Non-Small Cell Lung Cancer

NCT02319408
completedphase_2

Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly

NCT02992886
withdrawnphase_1

Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)

NCT03480867
terminatedphase_2

Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer

NCT00216086

Clinical Trials (5)

Showing 5 of 5 trials
NCT05739084

Gene Signatures Searching of Sensitivity/Resistance to Neoadjuvant Radiotherapy in Patients With Resectable STS

Unknown
NCT02319408Not Applicable

Immune Boost In Non-Small Cell Lung Cancer

Completed
NCT02992886Phase 2

Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly

Completed
NCT03480867Phase 1

Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)

Withdrawn
NCT00216086Phase 2

Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer

Terminated

All 5 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
5